Exelixis (EXEL) Tops Q2 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Exelixis (EXEL) Tops Q2 EPS by 9c

Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 9, 2022 4:05 PM EDT

- Total Revenues of $419.4 million, Cabozantinib Franchise Revenues of $347.0 million -
- GAAP Diluted EPS of $0.22, Non-GAAP Diluted EPS of $0.28 -
- Conference Call and Webcast Today at 5:00 PM Eastern Time -

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

In the second quarter of 2022, Exelixis continued to execute across each of the... More